Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

EJ Gibson,1 N Begum,1 I Koblbauer,1 G Dranitsaris,2 D Liew,3 P McEwan,4 AA Tahami Monfared,5,6 Y Yuan,7 A Juarez-Garcia,7 D Tyas,8 M Lees9 1Wickenstones Ltd, Didcot, UK; 2Augmentium Pharma Consulting Inc, Toronto, ON, Canada; 3Department of Epidemiology and Preventive Medicine, Alfred Hospital, Mona...

Full description

Bibliographic Details
Main Authors: Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Tahami Monfared AA, Yuan Y, Juarez-Garcia A, Tyas D, Lees M
Format: Article
Language:English
Published: Dove Medical Press 2018-03-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Immuno-oncology
metastatic melanoma
nivolumab
dacarbazine
Markov
partitioned survival
Online Access:https://www.dovepress.com/modeling-the-economic-outcomes-of-immuno-oncology-drugs-alternative-mo-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/modeling-the-economic-outcomes-of-immuno-oncology-drugs-alternative-mo-peer-reviewed-article-CEOR

Similar Items